Navigation Links
Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research

III development as part of a collaboration between sanofi-aventis and Regeneron.

S-1 is a novel oral fluoropyrimidine that combines three investigational agents: tegafur, a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine) which inhibits dihydropyrimidine dehydrogenase enzyme; and oteracil (potassium oxonate), a gastrointestinal side effect corrector. The Phase III data to be presented evaluate the addition of cisplatin to S-1 in advanced gastric cancer. S-1 is marketed in Japan by Taiho for a variety of indications including gastric cancer. Sanofi-aventis is leading the development of the compound outside of Japan and in some Asian countries.

TroVax(R) is a therapeutic cancer vaccine developed in collaboration with Oxford BioMedica. It targets the tumor antigen 5T4, broadly distributed in a wide range of solid tumors. The presentation will include new data from two Phase II trials of TroVax(R) in renal cancer.

Finally, the first outcomes of the innovative program "My Child Matters," a unique humanitarian pediatric cancer initiative in developing countries co- sponsored by sanofi-aventis and the International Union Against Cancer (UICC), will be presented.

Details on the key studies to be presented at the meeting during podium presentations and poster discussions are as follows:

Eloxatin(R) (oxaliplatin injection) clinical studies:

Abstract # 4007 - Oxaliplatin/5FU/LV in the adjuvant treatment of colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years.

    -- A long-term update including disease-free-survival and overall survival

       data from the MOSAIC study, which evaluates the role of

       oxaliplatin/5FU/LV (FOLFOX4) as adjuvant treatment for stage II and III

       colon cancer, will be presented.

    -- Sunday, June 3, 8:15 AM - 8:30 AM, E Arie Crown Theatre, Oral

       Presentation.

Abstract # 4067 - N9741:
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014 /PRNewswire/ ... a leading provider of medication and supply management ... a conference call Thursday, July 31, to discuss ... , Omnicell Second Quarter 2014 earnings conference ... 1:30 p.m. PTWho:  , Randall Lipps, chairman, president ...
(Date:7/24/2014)... and MENLO PARK, Calif. , July 24, ... ("DelMar" "the company") announced today that the company,s board of ... December 31 to June 30. Accordingly, DelMar will file a ... Jeffrey Bacha , president and CEO of DelMar ... step in achieving our goal of obtaining a senior exchange ...
(Date:7/24/2014)... , July 24, 2014 LSI Medience ... an Agreement with Kineticos, a Raleigh-Durham, ... Kineticos will support LSI Medience in identifying opportunities ... to demonstrate utility in clinical trials. ... utility in diagnosis of sepsis, prognosis of septic ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2
... , HUNTINGTON BEACH, California and ... cancer diagnostics, today announced the,inclusion of its breast cancer ... on the primary therapy of early breast,cancer. The recommendations ... will appear in the August print edition. , ...
... LAUSANNE, Switzerland, June 23 Debiopharm Group,(Debiopharm), ... on the development of prescription drugs that target unmet ... names Moapar(R),and Salvapar(R)), was launched in Germany in May ... was also launched on a preliminary basis in,Belgium. The ...
Cached Medicine Technology:Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations 2Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 “You have a ... than 500 people and their loved ones across the U.S. ... a brain tumor diagnosis is typically met with confusion and ... new and difficult vocabulary, and make critical decisions about a ... tumor diagnosis is accompanied by a sense of isolation and ...
(Date:7/25/2014)... The North America Artificial lift market report defines ... analysis and forecast of revenue. The artificial lift market in ... in 2013 to around $7 billion by 2018, at a ... through the TOC of North America artificial lift market report, ... provides a glimpse of the segmentation in North America Artificial ...
(Date:7/25/2014)... Providence, RI (PRWEB) July 25, 2014 ... Island Quality Improvement Organization (QIO) was recently awarded ... from the Centers for Medicare & Medicaid Services ... to fourteen organizations across the United States, represent ... In order to successfully execute the contract initiatives, ...
(Date:7/25/2014)... Health Advocate™, Inc., the nation’s leading healthcare ... Corporation, is introducing its newest solution in an upcoming ... Quality. , The webinar will be held twice on ... at 2 PM ET. For more information or to ... or call 866.799.2655. , In an environment of escalating ...
(Date:7/25/2014)... July 25, 2014 -- The Elizabeth Glaser Pediatric ... between the Medicines Patent Pool (MPP) and Gilead ... fumarate (TAF), a promising new HIV medication. The ... Conference (AIDS 2014) in Melbourne, Australia. , ... trials, early data suggests it could be a ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 2Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 2Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 3Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 4Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3
... updated the NCCN Guidelines for Venous Thromboembolic Disease, which ... (PE), and is a common condition in people with ... graduated compression stockings in prophylaxis and treatment, and a ... May 20 The National Comprehensive Cancer Network (NCCN) ...
... Alliance designed to benefit Californians with medical ... Medical Association (CMA), representing 35,000 physicians in ... the MedicAlert Foundation, the leading nonprofit providing ... teamed up to provide patients living with ...
... counseling also proved cost-effective, study finds , , WEDNESDAY, ... program that promoted exercise, healthy eating and quitting ... to moderate chronic obstructive pulmonary disease (COPD) and ... patients in the study were randomly assigned to ...
... Market is Reflected in Burgeoning Pipeline of More than ... from Decision ResourcesWALTHAM, Mass., May 20 Decision Resources, ... for pharmaceutical and healthcare issues, finds that the launch ... over the next 10 years will drive the type ...
... partnership with Axway to provide innovative solutions ... technologists to address the challenges of implementing ... cost-effective manner.BELLEVUE, Wash., May 20 Edifecs, ... simplification and systems interoperability, and Axway, a ...
... Directors of BD (Becton, Dickinson and Company) (NYSE: ... per common share, payable on June 30, 2009 to holders ... rate is $1.32 per share. About BD BD is ... sells medical devices, instrument systems and reagents. The Company is ...
Cached Medicine News:Health News:NCCN Updates Supportive Care Guidelines for VTE 2Health News:NCCN Updates Supportive Care Guidelines for VTE 3Health News:California Medical Association Joins MedicAlert Foundation to Offer Medical Identification for Members and Patients 2Health News:Healthier Lifestyle Can Cut COPD Symptoms 2Health News:The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market 2Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 2Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 3Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: